Stock listing

OTC:THMO ThermoGenesis Holdings, Inc. Stock

Follow ThermoGenesis Holdings, Inc. into a list and get an email when it puts out news.

ThermoGenesis Holdings, Inc. logo
Ticker
OTC:THMO
Asset type
Stock
Exchange
OTC
Currency
USD

ThermoGenesis Holdings, Inc. on 6ix

Calls
7 calls with a replay · 7 with a transcript · latest Nov 13, 2023
Decks
18 decks · latest Jan 10, 2022

Team and board

Officers

OfficerRole
Haihong ZhuCEO
Chris XuExecutive Chairman of the Board

Board

DirectorRole
Chris XuExecutive Chairman of the Board

Events

Results days

QuarterResults
Q1 2024May 17, 2024 · After close
Q4 2023Mar 28, 2024 · After close
Q3 2023Nov 13, 2023 · After close
Q2 2023Aug 10, 2023 · After close
Q1 2023May 15, 2023 · After close
Q4 2022Mar 30, 2023 · After close
Q3 2022Nov 10, 2022 · After close
Q2 2022Aug 11, 2022 · After close
Q1 2022May 19, 2022 · After close
Q4 2021Mar 28, 2022 · After close
All 14 quarters
QuarterResults
Q3 2021Nov 12, 2021 · After close
Q2 2021Aug 12, 2021 · After close
Q1 2021May 13, 2021 · After close
Q4 2020Mar 17, 2021 · After close

Open Events

Decks

DeckKindSlidesDate
H. C. Wainwright BioConnect Conference 2022Conference24 slidesJan 10, 2022
H.C. Wainwright 23rd Annual Global Investment Conference 2021Conference19 slidesSep 15, 2021
Corporate Update (May 2020)Corporate update18 slidesMay 14, 2020
Q3 2019 Earnings PresentationEarnings26 slidesNov 20, 2019
Cesca Therapeutics — BIO Investor Forum, San Francisco 2019Conference25 slidesOct 22, 2019
Cesca Therapeutics — HC Wainwright 21st Annual Global Investment Conference (September 2019)Conference20 slidesSep 11, 2019
Cesca Therapeutics — BIO CEO & Investor Conference 2019Conference21 slidesFeb 13, 2019
Cesca Therapeutics — Biotech Showcase 2018Conference21 slidesJan 16, 2018
Cesca Therapeutics — Investor Presentation (November 2017)Investor deck24 slidesNov 15, 2017
Cesca Therapeutics — Presentation to Dawson James Securities (May 2017)Conference22 slidesMay 11, 2017
All 18 decks
DeckKindSlidesDate
Cesca Therapeutics — Investor Presentation (May 2014)Investor deck22 slidesMay 2014
Merger or Acquisition (January 2014)Merger or acquisition24 slidesJan 29, 2014
American Association of Blood Banks Annual Meeting 2013Conference12 slidesOct 16, 2013
Merger or Acquisition (July 2013)Merger or acquisition30 slidesJul 18, 2013
Merger or Acquisition (July 2013)Merger or acquisition30 slidesJul 17, 2013
Cesca Therapeutics — Merger or Acquisition (July 2013)Merger or acquisition29 slidesJuly 2013
Investor Presentation (June 2011)Investor deck18 slidesJune 2011
Investor Presentation (June 2010)Investor deck24 slidesJune 2010

Open Decks

Financials

Annual, in USD

Income statement

LineFY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue9.45M10.5M9.29M9.74M13.0M9.67M14.5M11.9M16.0M16.0M
Cost of revenue7.51M7.77M5.80M8.48M7.35M7.48M8.69M9.19M11.3M10.1M
Gross profit1.93M2.71M3.49M1.26M5.70M2.19M5.84M2.74M4.75M5.89M
Research and development1.28M1.66M2.21M2.48M2.40M3.01M2.50M3.23M5.94M3.47M
Selling, general and administrative6.92M7.24M8.52M5.73M6.38M8.29M10.9M8.23M10.7M8.49M
Operating income-8.61M-6.19M-7.23M-8.89M-4.73M-43.5M-9.37M-10.9M-14.9M-9.04M
Depreciation and amortization1.15M926.0K633.0K742.0K805.0K670.0K830.0K1.17M1.35M993.0K
EBITDA-7.46M-5.27M-6.60M-8.15M-3.93M-42.9M-8.54M-9.70M-13.5M-8.05M
Interest expense10.0M5.62M6.10M7.91M4.48M2.70M20.5M7.99M14.0K6.00K
Income before tax-18.9M-11.8M-11.9M-16.8M-10.1M-45.7M-29.8M-18.6M-14.9M-9.03M
Income tax9.14M5.07M6.40M7.44M3.83M-4.73M-673.0K7.95M35.0K-403.0K
Net income-18.0M-11.3M-11.4M-16.4M-9.50M-39.7M-29.1M-18.6M-14.9M-8.63M
Earnings per share, basic-7.59-20.45-43.41-117.20-151.09-971.34-1,320.40-2,778.48-3,312.96-3,206.17

Balance sheet

LineFY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash and equivalents2.00M4.18M7.28M7.16M3.16M2.40M3.62M5.83M3.36M14.8M
Receivables949.0K1.86M733.0K1.38M1.28M1.51M3.70M3.17M5.13M4.69M
Inventory1.41M3.33M5.37M5.88M3.48M4.49M3.62M3.59M4.60M5.61M
Current assets5.18M10.9M15.0M15.3M9.52M8.63M11.2M12.8M13.3M25.3M
Property, plant and equipment1.83M2.15M2.03M2.56M3.00M2.33M2.96M2.94M
Goodwill0781.0K781.0K781.0K781.0K781.0K13.2M13.2M13.2M13.3M
Total assets11.2M19.4M20.7M20.9M15.2M14.6M46.9M49.9M50.8M62.9M
Accounts payable948.0K820.0K1.28M1.37M1.45M2.42M1.60M2.65M5.08M3.59M
Current liabilities11.8M11.5M6.35M6.14M6.68M6.37M4.52M5.54M7.95M6.38M
Long-term debt9.24M6.63M1.41M1.17M6.70M3.50M2.49M
Total debt10.6M10.4M10.5M7.68M5.69M3.39M7.69M3.95M3.19M
Total liabilities14.8M16.1M17.3M15.0M14.3M7.88M16.1M17.6M15.9M14.2M
Shareholders' equity-3.58M3.32M3.40M5.87M916.0K6.73M30.8M32.3M34.9M48.7M
Shares outstanding2.37M551.0K262.1K139.5K62.9K40.9K22.0K6.69K4.48K2.69K

Cash flow

LineFY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations-3.72M-7.28M-6.62M-14.4M-3.26M-6.98M-7.21M-9.63M-10.6M-7.84M
Capital spending-1.73M-400.0K-93.0K-23.0K-182.0K-1.24M-375.0K-710.0K-587.0K-402.0K
Free cash flow-5.45M-7.68M-6.71M-14.4M-3.44M-8.22M-7.59M-10.3M-11.2M-8.24M
Cash from investing-93.0K-23.0K-182.0K-1.24M-1.40M-375.0K-710.0K-587.0K
Cash from financing3.28M4.59M6.83M17.4M4.20M7.11M5.37M12.8M-189.0K15.8M
Dividends paid-3.63M-17.0M
Share buybacks12.5M910.0K6.66M-134.0K-8.00K-129.0K-68.0K
Change in cash-2.18M-3.10M119.0K3.00M757.0K-1.11M-2.21M2.48M-11.5M7.93M

Open Financials

Cap table

Built by 6ix from ThermoGenesis Holdings, Inc.’s releases

Common shares
15,847,517
Fully diluted
15,847,517

Fully diluted

LineShares
Common shares15,847,517

Share count over time

CountShares
Nov 22, 202615,847,517

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Vivian Liu
Other companies: Aytu BioPharma, Inc. (Director, Compensation Committee Chair · Since at least Jul 1, 2022); Apricus Biosciences Inc (Executive Vice President, Director · Dec 31, 2010 – Dec 31, 2010 · Past)
Director · Jun 21, 2022 – Jun 21, 2022 · Past
Biao XiDirector · Jul 14, 2023 – Jul 14, 2023 · Past
Chris XuExecutive Chairman of the Board · Since at least Nov 5, 2026
Haihong ZhuCEO · Since at least Jan 13, 2022
James XuDirector · Jul 14, 2023 – Jul 14, 2023 · Past
Jeffery CaubleChief Financial Officer · Jun 4, 2020 – May 27, 2021 · Past
Thomis JosephDirector · Jun 4, 2020 – Jun 4, 2020 · Past

Open People

Log in to ask 6ix AI your own questions about ThermoGenesis Holdings, Inc.